Tammy Wichman, MD
Critical Care Medicine · Omaha, NENPI 1780788844
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,150 of the $11,504 with a category attached, or 96.9%. Merck accounts for 96.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $11,261 and has fallen 99.6% since, to $41 in 2025.
Across 5 payments — averaging $2300.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$11K
- United Therapeutics Corporation$243
- Actelion Pharmaceuticals US, Inc.$112
Across 58 payments — averaging $22,042 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- Janssen Research & Development, LLC$87K
- United Therapeutics Corporation$37K
- Cumberland Pharmaceuticals, Inc.$35K
What the payments were for
- Consulting fees$11,15097%
- Food & beverage$3543%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $11,150 |
| United Therapeutics Corporation | 3 | $243 |
| Actelion Pharmaceuticals US, Inc. | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few critical care medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 324 | $4,064,628 |
| Tyvaso DpiTreprostinil | 133 | $3,133,011 |
| AdempasRiociguat | 166 | $2,287,414 |
| UptraviSelexipag | 78 | $1,806,708 |
| WinrevairSotatercept-Csrk | 34 | $475,372 |
| Orenitram ErTreprostinil Diolamine | 105 | $436,255 |
| Ambrisentan | 89 | $307,202 |
| TracleerBosentan | 12 | $148,195 |
| Tadalafil | 144 | $137,073 |
| AdcircaTadalafil | 18 | $48,808 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,482 |
| EliquisApixaban | 25 | $18,553 |
| Sildenafil Citrate | 157 | $16,422 |
| Pirfenidone | 11 | $9,928 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $8,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer | $112 | $6,019,532414 claims |
| MerckWinrevair | $11,150 | $475,37234 claims |
| United Therapeutics CorporationAdcirca | $243 | $48,80818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other critical care medicine in Omaha
- Jason LambrechtOmaha$1K
- Steven LiscoOmaha$551
- Andrew PattersonOmaha$454
- Dominique SamuelOmaha$393
- Sabin BistaOmaha$370
- Robert PlambeckOmaha$289
- Kara ReyesOmaha$69
- Zahid IqbalOmaha$52
- Ashley CarneOmaha$37
- Terry BrownOmaha$36
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.